A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)
A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)
Primary Objective:
To evaluate long-term safety of alemtuzumab.
Secondary Objectives:
The total duration per participants was up to 5.6 years.
As per Study Investigator discretion, participants can be treated with additional courses of alemtuzumab or any commercialized DMTs.
All participants who completed CAMMS03409 were allowed into the study, which might include specific vulnerable populations. If the investigator decided to treat a participant with a course of alemtuzumab, appropriate cautionary measures were applied as indicated in the approved labelling, or, in ex-European Union countries where Lemtrada was not approved, according to the investigator's brochure.
Inclusion criteria:
Participant had completed at least 48 months of the Extension Study CAMMS03409. Signed written informed consent form.
Exclusion criteria:
Participant participating in another investigational interventional study.
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
CABA, C1061ABD, Argentina
Sittard-Geleen, 6162BG, Netherlands